Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 122,159

Document Document Title
WO/2016/206551A1
The present invention provides an application of a Src protein inhibitor comprising N-(2-chloro-6-methylphenyl)-2-{6-[4-(3-hydroxyethyl)-1-piper azinyl]-2-methyl-4-pyrimidinylamino}-5-thiazole methanamide(formula I) in a drug for the pre...  
WO/2016/210120A1
The invention relates to the treatment of neurodegenerative disorders with ceramidase inhibitor.  
WO/2016/210372A3
Disclosed is a method of treating a subject who has a neurological disease. The neurological disease may be associated with altered C9ORF72 protein activity. In one aspect, the method includes a step of administering an effective dose of...  
WO/2016/207413A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun N-terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding s...  
WO/2016/208775A1
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep d...  
WO/2016/206699A1
Title: Iron carbohydrate complex for treatment of fetal metal defi- ciency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of ...  
WO/2016/208695A1
Disclosed is a means that can be used for modifying a biologically or pharmacologically active substance from a form incapable of permeating the blood-brain barrier to a form capable of permeating the blood-brain barrier. Also disclosed ...  
WO/2016/208045A1
The present invention addresses the problem of providing a medicinal composition for treating ataxia associated with spinocerebellar degeneration, said medicinal composition reducing a risk of side effects caused by an increase in parath...  
WO/2016/208556A1
The present application provides a relaxing composition including precious metal microparticles and a method for relaxing a subject by the composition.  
WO/2016/206172A1
Provided is a use of MicroRNA-7 in preparation of drugs for suppressing gliosis of a nervous system. Overexpressing the MicroRNA-7 in a rat retina Muller cell line can reduce GMFB expression and inhibit generation of inflammatory factors...  
WO/2016/209765A1
A pharmaceutical composition containing a benzhydrylsulfinylacetamide antidepressant, and either or both of an SSRI uptake inhibitor and/or a stimulating antidepressant has been shown to be effective in ameliorating symptoms of dementia,...  
WO/2016/210144A1
Described are compositions of matter and protocols useful for treatment of neurological and other disorders associated with inflammatory activities. In some embodiments the invention provides means of modulating neuroinflammation through...  
WO/2016/210180A2
Methods are provided herein for treating mania in mood disorders and other neurological diseases or disorders. The methods provided herein comprise administering a VMAT2 inhibitor to a subject in need thereof. A VMAT2 inhibitor useful in...  
WO/2016/206573A1
The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making a...  
WO/2016/203347A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutica...  
WO/2016/203404A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/205631A1
The invention relates to methods for preventing stress-associated disorders. These disorders may be treated with a serotonin 2c receptor (5-HT2CR) antagonist prior to, during, or following a stress-related event. Stress-associated disord...  
WO/2016/203220A1
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.  
WO/2016/203400A1
The present invention relates to aryl analogs Formula (I), pharmaceutical compositions containing them and their use as Nrf2 regulators.  
WO/2016/205270A8
The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides vario...  
WO/2016/205226A1
The methods of the present invention are useful for determining whether an individual has or is at risk of developing an affective disorder by detecting the expression level of connective tissue growth factor (CTGF) in a biological sampl...  
WO/2016/203405A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/204153A1
The present invention provides a compound represented by general formula (Ia) or a pharmacologically acceptable salt thereof. In general formula (Ia), the two R each independently represent a C1-3 alkyl group or the like, and R1, R2, and...  
WO/2016/203221A1
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.  
WO/2016/201524A1
The present invention provides a process for the preparation of metal ion complexes, the process comprising contacting a metal in the form of particles with a chelating agent in solid form and, while the metal is in contact with the chel...  
WO/2016/204988A1
Disclosed is a method of decreasing an amount of protein aggregate in a cell comprising contacting the cell with a compound of the formula (I): wherein R1, R2, and R3 are as defined herein, in an amount sufficient to induce autophagy in ...  
WO/2016/203217A1
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.  
WO/2016/203223A1
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.  
WO/2016/203401A1
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.  
WO/2016/205739A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2016/203239A1
The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing ...  
WO/2016/202800A1
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositid...  
WO/2016/202161A1
The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the prepa...  
WO/2016/204268A1
[Problem] To provide a compound useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM). [Solution] The present inventors have studied on compounds each of which has a positive allosteric modulating activity (a PAM activi...  
WO/2016/204230A1
A stem cell administration method includes an administration step for injecting a stem cell-containing solution containing stem cells collected from an animal (donor animal) or subcultured stem cells obtained by subculturing the stem cel...  
WO/2016/203218A1
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.  
WO/2016/203406A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  
WO/2016/205270A1
The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides vario...  
WO/2016/202453A1
A combination composition comprising as active components, in synergistically effective amounts a huperzine of natural or synthetic origin, a pharmaceutically acceptable salt thereof or a plant extract containing huperzine, and at least ...  
WO/2016/203402A1
The design and synthesis of a novel bis-furan scaffold tailored for high efficiency at inhibiting transthyretin amyloid formation is reported. In vitro results show that the discovered compounds are more efficient inhibitors of amyloid f...  
WO/2016/199878A1
Provided is a sigma-receptor binding agent that is characterized by containing an alkyl ether derivative represented by general formula [1] or a salt thereof. (In the formula, R1 and R2 are the same or different and indicate a hydrogen a...  
WO/2016/201096A1
The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ot7-nAChR, and methods of preparing these compounds and compositions, ...  
WO/2016/199906A1
The purpose of the present invention is to provide a novel low-molecular-weight compound which exhibits orexin receptor agonist activity and is expected to be useful as a prophylactic agent or therapeutic agent for narcolepsy and the lik...  
WO/2016/197877A1
Disclosed is a pharmaceutical composition for the treatment of depression, wherein the pharmaceutical composition is comprised of the following herbs in weight parts: 2-10 parts Ramulus Cinnamomi, 2-10 parts Rhizoma Zingiberis, 2-10 part...  
WO/2016/201373A1
The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment of REM sleep behavior disor...  
WO/2016/201086A1
The present invention generally relates to compositions and methods for stimulating ADAMI O-mediated nonamyloidogenic proteolysis of amyloid precursor protein. One aspect of the invention provides a method of preventing or treating Alzhe...  
WO/2016/199796A1
[Problem] To provide a novel non-peptidic compound that can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor which contains, as an active ingredient, a compound represented by chemical formul...  
WO/2016/201246A1
The disclosure provides, among other things, compositions and methods useful for maintaining splicing fidelity in a cell. The compositions can include a compound that modulates the expression level or activity of one or more components o...  
WO/2016/201434A3
Provided herein are stable compositions containing anti-tau antibodies. In particular, compositions containing C2N-8E12 anti-tau antibody and a buffering system are provided herein.  
WO/2016/200827A1
A compound, or a pharmaceutically acceptable salt thereof, having a formula I of: (I) wherein Ar is an arylene or heteroarylene; R1 has a structure of: (II) wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof; X ...  

Matches 551 - 600 out of 122,159